Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis
- JAMA Neurology
- DOI: 10.1001/jamaneurol.2026.3439
Sandra Kallin, Anders Svenningsson, Ola Olén, Charlotte Hedin, Jan Lycke, and Peter Alping
Creative Commons Attribution 4.0 International License (CC-BY)
Temporal Trends in the Incidence and Prevalence of Multiple Sclerosis in Sweden, 2001–2021
- Neuroepidemiology
- DOI: 10.1159/000552732
Astrid Pedersen, Fredrik Sandesjö, Peter Alping, Thomas Frisell, Fredrik Piehl, Katharina Fink, and Kyla A. Mckay
Creative Commons Attribution 4.0 International License (CC-BY)
Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B-Cell Depletion
- European Journal of Neurology
- DOI: 10.1111/ene.70656
Peter Alping, Anton Öberg Sysojev, Fredrik Piehl, and Thomas Frisell
Creative Commons Attribution 4.0 International License (CC-BY)
Completeness and generalizability of the Swedish MS register
- European Journal of Epidemiology
- DOI: 10.1007/s10654-025-01276-z
Peter Alping, Thomas Frisell, Anna He, Jan Hillert, Katharina Fink, and Kyla A. McKay
Creative Commons Attribution 4.0 International License (CC-BY)
Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis
- Multiple Sclerosis Journal – Experimental, Translational and Clinical
- DOI: 10.1177/20552173251314118
Fredrik Sandesjö, Peter Alping, Katharina Fink, Ronny Wickström, Fredrik Piehl, Thomas Frisell, and Kyla A McKay
Creative Commons Attribution 4.0 International License (CC-BY)
Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
- Annals of Neurology
- DOI: 10.1002/ana.27026
Yihan Hu, Thomas Frisell, Peter Alping, Huan Song, Yudi Pawitan, Fang Fang, and Fredrik Piehl
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study
- Annals of Neurology
- DOI: 10.1002/ana.26914
Peter Alping, Martin Neovius, Fredrik Piehl, and Thomas Frisell
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
- Annals of Neurology
- DOI: 10.1002/ana.27012
Fredrik Piehl, Peter Alping, Suvi Virtanen, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Johan Mellergård, Petra Nilsson, Tomas Olsson, Jonatan Salzer, Anders Svenningsson, and Thomas Frisell
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
Disease-modifying therapies in multiple sclerosis: A focused review of rituximab
- Basic & Clinical Pharmacology & Toxicology
- DOI: 10.1111/bcpt.13932
Peter Alping
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
- Multiple Sclerosis
- DOI: 10.1177/13524585231161492
Katharina Fink, Agnes Gorczyca, Peter Alping, Simon Englund, Susan Farmand, Annette M. Langer-Gould, Fredrik Piehl, Kyla McKay, Thomas Frisell, and Neda Razaz
Creative Commons Attribution 4.0 International License (CC-BY)
Pharmacoepidemiological Studies of Rituximab and Other Recent Therapies in Multiple Sclerosis
- Thesis
- Karolinska Institutet
- Sweden
Peter Alping
Creative Commons Attribution 4.0 International License (CC-BY)
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
- Neurology
- DOI: 10.1212/WNL.0000000000011545
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, and Fredrik Piehl
Creative Commons Attribution 4.0 International License (CC-BY)
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- JAMA Neurology
- DOI: 10.1001/jamaneurol.2019.3365
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, and Thomas Frisell
Copyright 2019 American Medical Association. All Rights Reserved.
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
- Annals of Neurology
- DOI: 10.1002/ana.25701
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, and Thomas Frisell
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
- Epidemiology
- DOI: 10.1097/EDE.0000000000000948
Peter Alping, Fredrik Piehl, Annette Langer-Gould, Thomas Frisell, and COMBAT-MS Study Group
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
- Neurology
- DOI: 10.1212/wnl.0000000000003331
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg, Peter Sundström, Jan Lycke, Fredrik Piehl, and Anders Svenningsson
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
- Annals of Neurology
- DOI: 10.1002/ana.24651
Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer, Anna Björck, Markus Axelsson, Clas Malmeström, Katharina Fink, Jan Lycke, Anders Svenningsson, and Fredrik Piehl
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)